FOXO4-DRI
Aliases: FOXO4-D-retro-inverso peptide
Last verified: 2026-09-24
The short version
FOXO4-DRI is the best-known 'peptide senolytic' — and an excellent example of how one Cell study can spawn an entire gray industry. What has actually been shown: in fast-aging mice, late-life treatment improves several functions. What has not been shown: anything in humans, any long-term outcome, the safety of any dose, and — critically — whether senolysis should be done continuously at all (most of the academic debate now favors a 'pruning' approach, not courses). The gray narrative sells 'removal of old cells' as a routine protocol, which is like selling chemotherapy as a vitamin: the idea makes sense, context is everything.
Identity & type
- Molecular type
- peptide
- Origin
- Designed by converting the FOXO4 p53-binding sequence into a retro-inverso form (D-amino acids, reversed order) for protease resistance.
Mechanism of action
A D-retro-inverso peptide that disrupts the FOXO4–p53 interaction in senescent cells; released p53 triggers death of senescent cells (senolysis) without touching healthy cells — in mice it 'improved' healthspan and organ function.
not confirmed in humans
Dosing & routes
Official / clinical context
No official context exists.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Popular in 'longevity' circles: 1–5 mg SC 1–2× weekly in 'cycles' of a few weeks, often combined with fisetin/quercetin. Reports are purely subjective ('energy, recovery') and inseparable from expectation.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No approved product. Mouse studies used intermittent high-dose courses to clear senescent cells.
Duration: Preclinical only.
The 2017 senolytic mouse paper is the entire evidentiary basis.
Community (anecdotal)
1–2 mg SC 3× weekly in self-experimentation reports.
- Cycle:
- 3–4 week 'bursts'.
- Break:
- Months between bursts.
Self-experimentation with a senolytic peptide whose entire human evidence base is the person injecting it.
Human evidence
None — not even phase 1.
Preclinical evidence
One landmark study (Cell 2017) plus a senolytic branch that exploded after 2015; but genetic approaches to senolysis (p16-INK4a/AP20187 systems) show the effect is context- and model-dependent — translatability to humans is the open question of the whole field, not of this substance.
Known risks
- Theoretical: impaired wound healing and anti-tumor surveillance with chronic senolysistheoretical
- Unknown identity/purity of gray retro-inverso peptide synthesescharacterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Everything in humans — from dose to effect to safety
- Whether senolysis should be a routine or an on-demand intervention
Frequently asked questions
References
- Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 2017
- Senolytics field reviews (post-2018) — translatability debates